author-photo

Daniel Gipe

Regeneron

24

Papers

2219

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (392)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (171)
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment ☆

2017 International Journal of Cardiology
Show All
- Source
- Cite
- Save
Citations (14)
Abstract 16875: Functional Analysis of Low Density Lipoprotein Receptor Variants in Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of Low Density Lipoprotein Receptor Activity

2017 Circulation
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Efficacy of Evinacumab, A Monoclonal Antibody to ANGPTL3, In Homozygous Familial Hypercholesterolemia

2017 Journal of Clinical Lipidology
Show All
- Source
- Cite
- Save
Citations (4)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

2017 Journal of Clinical Lipidology
Show All
- Source
- Cite
- Save
Citations (41)
Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies

2016 Journal of Clinical Lipidology
Show All
- Source
- Cite
- Save
Citations (8)
Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3

2016 Circulation
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

2015 Journal of Clinical Lipidology
Show All
- Source
- Cite
- Save
Citations (307)
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

2015 European Heart Journal
Show All
- Source
- Cite
- Save
Citations (368)